This study was stimulated by the clinical observation of a rapid response of a chilblain lupus patient to treatment with JAK1/2-kinase inhibitor ruxolitinib. We investigated the in vivo expression of phospho-JAK2 in CLE skin samples as well as the immunomodulatory in vitro effect of ruxolitinib in cultured immortalized keratinocytes and in a 3D human epidermis model (epiCS). Our results demonstrate that ruxolitinib significantly decreases the production of CLE-typical cytokines (CXCL10, CXCL9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.
| CLINICAL OBSERVATION
A 69-year-old woman presented to our department with photosensitive erythrosquamous plaques and nodules with acral distribution ( Figure 1A ). Histological and immunohistological investigations revealed a mild interface dermatitis with mucin deposits accompanied by lesional expression of interferon-regulated proteins (MxA, CXCL10) and enhanced ANA titres (1:80, granular pattern), thus confirming the diagnosis of chilblain lupus erythematosus (ChLE). Importantly, skin lesions appeared after discontinuation of ruxolitinib, a JAK1/2-kinase inhibitor which the patient had been prescribed for her primary myelofibrosis. After re-initiation of ruxolitinib treatment, skin lesions resolved completely (for further details on the case see [1] ).
| OBJECTIVE
We recently observed a similarly successful treatment with ruxolitinib in a case of dermatomyositis (DM). [2] DM is also an IFNassociated cutaneous autoimmune disease. Both cases taken together prompted us to hypothesize that the JAK pathway might play a crucial role in this disease spectrum, and that inhibition of this pathway might prevent the expression of LE-typical cytokines in the epidermis.
We therefore analysed the JAK2 expression in skin biopsies of patients suffering from different subsets of cutaneous lupus erythematosus (CLE) and compared them to psoriasis (Pso), atopic dermatitis (AD), lichen planus (LP) and healthy controls (HC). Next, we investigated the functional impact of ruxolitinib on the induction of LE-characteristic cytokines using an in vitro cell culture model of CLE (RNA/DNAstimulated HaCaTs). The results were confirmed in a three-dimensional human epidermis equivalent (epiCS).
| RESULTS

| High in vivo expression of activated phospho-JAK2 in CLE skin lesions
To investigate a possible role of JAK2 in CLE, we performed immunohistological stainings of lesional skin biopsies taken from patients with different subsets of CLE and controls using an antiphospho-JAK2-antibody (methods described in Appendix S1). 
BEDSIDE-TO-BENCH-LETTER
In our patient, the antiphospho-JAK2 immunohistochemistry revealed a strong expression of activated JAK2 in the epidermis similar to the expression of MxA and CXCL10 (lower and upper epidermis, Figure 1B ). Similar findings were observed for other CLE subsets (CDLE, SCLE) and lichen planus. In contrast, JAK2-phosphorylation in AD and Pso was significantly lower, and completely absent in HC (Appendix S1).
| Ruxolitinib inhibits in vitro expression of CLE-typical cytokines in immortalized keratinocytes
In CLE, the lesional inflammation is believed to be activated by endogenous nucleic acids, especially by immunostimulatory DNA and RNA motifs. [3] To investigate the effect of ruxolitinib in this inflammatory context, we used an established CLE in vitro model. [4] Cultured immortalized keratinocytes (HaCaT) were stimulated with synthetic DNA (poly(dA:dT)) and RNA (poly(I:C)) motifs ( Figure 1C ).
The effect of ruxolitinib on the expression of CXCL10 in the supernatant was measured by ELISA. In this in vitro model, ruxolitinib caused a significant decrease of CXCL10 and CXCL9 expression after stimulation with both poly(dA:dT) and poly(I:C) ( Figure 1C and Appendix S1).
| Ruxolitinib inhibits the expression of CLEtypical cytokines in a 3D epidermis model
Next, we repeated the experiment in a three-dimensional human epidermis equivalent (epiCS) ( Figure 1D ). Again, histological staining revealed that poly(I:C)-induced inflammation (CXCL10, MxA) was strongly reduced after ruxolitinib exposure. These results were confirmed by ELISA, thus demonstrating that ruxolitinib significantly reduces the levels of CXCL10, a known key driver of lesional inflammation in CLE.
[3]
| DISCUSSION
Ruxolitinib is a JAK inhibitor originally developed for the treatment of JAK2-mutated myeloproliferative neoplasms. Considering that, in our case, ChLE symptoms occurred after discontinuation of ruxolitinib, it is likely that ruxolitinib also has anti-inflammatory potential in autoimmune diseases. Ruxolitinib blocks IFN-induced STAT-1 phosphorylation in vitro, thereby inhibiting the pathway utilized by type I IFNs, a hallmark of CLE. [5] Ruxolitinib was shown to be a potent inhibitor of various immune cells in vivo, [6, 7] and studies on MRL/lpr mice indicate that ruxolitinib can significantly attenuate CLE-like lesions in vivo. [8] In humans, ruxolitinib has been shown to be effective in the treatment of patients suffering from psoriasis, alopecia areata and vitiligo. [5, 6] Inhibition of the activation of proinflammatory cytokines may explain the anti-inflammatory potential of ruxolitinib in our ChLE patient. This view is supported by our in vitro data demonstrating a significant ruxolitinib-mediated reduction of CXCL10, a key regulator of the CLE-typical interface dermatitis.
| Research plan for future in vivo experiments
The above in vivo data should be completed by in vivo analysis, ideally in our UV-inducible CLE mice model, based on the TREX1-knockout strain. In this analysis, skin lesions in 6-week-old mice will be induced by UVB treatment and treated with ruxolitinib or placebo control. Primary endpoint is the skin disease activity score on day 10.
Secondary endpoints are the histological inflammation score and the expression of CLE-typical proinflammatory cytokines (CXCL10, MxA) in skin and blood serum. For future clinical studies in human CLE, investigation of the efficacy of topical ruxolitinib will be of specific interest. This application form has been shown to be effective in other inflammatory diseases and is associated with only mild side effects when compared with systemic use. [9] The research plan is detailed in the Appendix S1.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article. 
L E T T E R S T O T H E E D I T O R
GSTP1 does not modify MC1R effects on melanoma risk
| BACKGROUND
Glutathione S-transferases (GSTs) are a group of enzymes that act to detoxify reactive oxygen species resulting from oxidative stress processes and melanin production. GSTP1 is a polymorphic gene encoding variant proteins involved in metabolism. The role of the rs1695*A/G GSTP1 Ile105Val polymorphism in cutaneous malignant melanoma (CMM) susceptibility remains controversial. Two recent meta-analyses reported that the GSTP1 105Val allele was associated with an increased risk of CMM. 1,2 However, it was concluded by the authors of both publications that additional studies with larger cohorts were required.
The melanocortin 1 receptor (MC1R) gene encodes a G-protein coupled receptor involved in the regulation of melanin production and the response to solar ultraviolet. 3 MC1R RHC-variant alleles exercise major influence on hair colour, skin colour and sun sensitivity. The association between MC1R and susceptibility to CMM and skin cancer in general has been described previously. 4, 5 A 2011 Spanish study reported that the GSTP1 polymorphism was associated with light coloured hair and increased CMM risk. Furthermore, the authors described a greater penetrance of CMM risk when the GSTP1 105Val allele was combined with MC1R RHC-variant alleles.
6,7
| QUESTIONS ADDRESSED
This study has further examined the association between rs1695*A/G GSTP1 Ile105Val polymorphism and CMM. In addition, we examined the previously described effect modification of the combination of GSTP1 Ile105Val with MC1R RHC-variant alleles in a cohort of Queensland control and CMM cases and CMM control and patient samples from Germany. This study included the largest population to date, a total of 27 574 participants.
| EXPERIMENTAL DESIGN & RESULTS
The Brisbane Nevus Morphology Study (BNMS) included a total of 738 participants, 342 at high risk of developing CMM were re- 
